92 research outputs found
Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes
Numerous clinical trials have established the value of antiplatelet therapies for acute coronary syndromes (ACS). Aspirin (ASA), thienopyridines (i.e., clopidogrel and ticlopidine) and GP IIb/IIIa antagonists comprise the major classes of antiplatelet therapies demonstrated to be of benefit in the treatment of ACS and for the prevention of thrombotic complications of percutaneous coronary intervention (PCI). Clopidogrel is beneficial when administered before and after PCI, and is more effective when combined with either ASA or GP IIb/IIIa inhibitors in preventing post-PCI complications, coronary subacute stent thrombosis, and thrombotic events in general. It is currently unclear whether a higher loading dose of clopidogrel (600 mg) is better than the standard loading dose (300 mg), how long therapy should continue, and which maintenance dose is optimal. The role of the GP IIb/IIIa antagonists in ACS is less clear due to conflicting data from several studies with different patient populations. Currently, it appears that the use of GP IIb/IIIa antagonists might be most beneficial in high-risk ACS patients scheduled to undergo PCI, who demonstrate non-ST-segment elevation myocardial infarction and elevated troponin levels. Copyright © 2008 Wiley Periodicals, Inc.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/58556/1/20362_ftp.pd
Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI
Platelet inhibition remains the core pharmacotherapy component in patients under-going emergency or primary percutaneous coronary interventions (PCI). This can be achieved using a number of intravenous and oral preparations. Intravenous (iv) antiplatelets include various glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors and the only available intravenous P2Y12 inhibitor, cangrelor. Available oral agents include aspirin and various P2Y12 inhibitors or their analogues. These are usually used in combination with the intention to maintain dual antiplatelet therapy (DAPT) for a period of time (generally up to 12 months) after the index PCI procedure.Understanding and appropriate use of antiplatelet agents are vital in optimizing clinical outcomes of patients with acute coronary syndromes, particularly in the emergency setting where the patient may be naïve to all pharmacological agents. In this review, an overview on antiplatelet therapy for patient needing emergency PCI is described, including evidence from important clinical trials and suggested anti-platelet therapy regimens by published clinical practice guidelines
Management of patients with unstable angina/non-ST-elevation myocardial infarction: a critical review of the 2007 ACC/AHA guidelines
Utilization of Glycoprotein IIB/IIIA Receptor Antagonists in the Management of Acute Coronary Syndrome: Focus on Patient Characteristics and Formulary Decisions
Retrospective, Observational Comparison of Eptifibatide vs Abciximab in Patients Undergoing Percutaneous Coronary Intervention
Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors
Efficacy and Safety of Tirofiban in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis
The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes
- …